Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.

Press Release - Vical Incorporated (VICL-NASDAQ)

wpe11.jpg (7184 bytes)

“We can apply our technology for vaccines; we can apply it for proteins, animal health applications, cancer. We are focusing on vaccines because vaccines are now probably the single most important medical advance that is going to be required in the next fifty years to deal with a variety of diseases as well as a variety of cancers. We are focused on one of the most lucrative applications of this technology.” - Vijay B. Samant (VICL) (Interview published February 15, 2007)

The Most Powerful Name In Corporate News and Information.

CURRENT ISSUE  |  COVER ARCHIVES  |   INDEX   |  CONTACT  |  FINANCIALS  |  MARKETING SERVICES   |   HOME PAGE


CEOCFO-Members Login
Become A Member!



 
Vical to Present at Upcoming Investor Conferences

Date: 5/12/2008 6:30:00 AM

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that Vical's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships at three upcoming investor conferences:

     *  Bank of America 2008 Health Care Conference (Las Vegas, May 13 - 15),

     *  FBR Capital Markets 12th Annual Spring Investor Conference
        (New York, May 28-29),

     *  Needham & Company Seventh Annual Biotechnology and Medical Technology
        Conference.

A webcast of the presentation at the Needham conference will be available live and archived through the events page at http://www.vical.com.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

    Contact:   Alan R. Engbring
               (858) 646-1127
               Website:  http://www.vical.com


SOURCE  Vical Incorporated
    -0-                             05/12/2008
    /CONTACT:  Alan R. Engbring of Vical Incorporated, +1-858-646-1127/
    /Web site:  http://www.vical.com/
    (VICL)

CO:  Vical Incorporated; Bank of America 2008 Health Care Conference; FBR
     Capital Markets 12th Annual Spring Investor Conference; Needham & Company
     Seventh Annual Biotechnology and Medical Technology Conference
ST:  California, Nevada, New York
IN:  MTC BIO
SU:  TDS
 
 
 
 
 

			
 

			

			
 

			

			
 

			

			
			



		

		
    


    

    
	

        

    

  







ceocfointerviews.com does not purchase or
make 

recommendation on stocks based on the interviews published.